Martins, J.R.B.; Moraes, L.N.; Cury, S.S.; Capannacci, J.; Carvalho, R.F.; Nogueira, C.R.; Hokama, N.K.; Hokama, P.O.M.
MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate. Int. J. Mol. Sci. 2021, 22, 10216.
https://doi.org/10.3390/ijms221910216
AMA Style
Martins JRB, Moraes LN, Cury SS, Capannacci J, Carvalho RF, Nogueira CR, Hokama NK, Hokama POM.
MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate. International Journal of Molecular Sciences. 2021; 22(19):10216.
https://doi.org/10.3390/ijms221910216
Chicago/Turabian Style
Martins, Juliana R. B., Leonardo N. Moraes, Sarah S. Cury, Juliana Capannacci, Robson Francisco Carvalho, Célia Regina Nogueira, Newton Key Hokama, and Paula O. M. Hokama.
2021. "MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate" International Journal of Molecular Sciences 22, no. 19: 10216.
https://doi.org/10.3390/ijms221910216
APA Style
Martins, J. R. B., Moraes, L. N., Cury, S. S., Capannacci, J., Carvalho, R. F., Nogueira, C. R., Hokama, N. K., & Hokama, P. O. M.
(2021). MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate. International Journal of Molecular Sciences, 22(19), 10216.
https://doi.org/10.3390/ijms221910216
